Antony Koblish, CEO, emphasized the company's continued execution on expanding its commercial footprint, improving operating discipline, and strengthening its patient-centric culture. TELA Bio ...
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and ...
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance
Management expects growth momentum to slow to low-single digits in Q4 due to uncertainties around NIH funding and tariffs. Adjusted operating margin is projected to be 100 to 150 basis points lower in ...
Hosted on MSN
Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships
Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a ...
Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback